{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-011487","form_type":"8-K","ticker":"HRTX","cik":"0000818033","company_name":"HERON THERAPEUTICS, INC. /DE/","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.348175+00:00","generated_at":"2026-06-17T07:26:45.962669+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Heron Therapeutics appoints Craig Collard as CEO, Adam Morgan as Chairman","bullets":["Craig Collard appointed CEO effective April 3, 2023, succeeding Barry Quart who stepped down.","Adam Morgan elected Chairman of the Board; CEO and Chairman roles are now separate.","Collard's compensation: $650,000 base salary, 75% target bonus, equity grants including 3M stock options and up to 4.25M performance-based options.","Board reduced to seven members as part of governance changes.","Departure of Barry Quart not due to any disagreement; he may assist with transition under a consulting agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-011487","json":"https://secwatch.observer/filing/0000950170-23-011487.json","markdown":"https://secwatch.observer/filing/0000950170-23-011487.md","text":"https://secwatch.observer/filing/0000950170-23-011487.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/818033/000095017023011487/0000950170-23-011487-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/818033/000095017023011487/hrtx-20230330.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:26:45.962669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be05a6d31a","claim":"Craig Collard was appointed as Chief Executive Officer at HERON THERAPEUTICS, INC. /DE/.","evidence_excerpt":"appointed Craig Collard as the Company’s Chief Executive Officer, effective April 3, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017023011487/0000950170-23-011487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"fe3cf6f9d0","claim":"Barry Quart departed as Chief Executive Officer at HERON THERAPEUTICS, INC. /DE/.","evidence_excerpt":"Mr. Collard succeeds Barry Quart, who will cease to serve as the Company’s Chairman, Chief Executive Officer and a director as of the Effective Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017023011487/0000950170-23-011487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"ffde4e000b","claim":"Adam Morgan was appointed as Chairman of the Board at HERON THERAPEUTICS, INC. /DE/.","evidence_excerpt":"appointed current director Adam Morgan to serve as Chairman of the Board, effective as of the Effective Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/818033/000095017023011487/0000950170-23-011487-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}